ClinicalTrials.gg
TerminatedNCT03860844ISAKIDSUpdated Sep 9, 2025Results posted

Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

A Phase 2 interventional study of Isatuximab and Dexamethasone or equivalent in Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, sponsored by Sanofi. Terminated at 41 sites in 16 countries. Open to participants aged 28 Days to 17 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
28 Days to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi — none open to participants now, none under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Sanofi.

Enrollment
5th of 10
67 · median 64
Started
2019
the only one that year
Phase 2
5 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 2, and was the 10th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

None of the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi is open now. The open studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, anywhere →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 28 Days to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Sanofi as a file.
02

Study summary

Primary Objective:

Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML)

Secondary Objectives:

  • Safety and tolerability assessments
  • Assessment of infusion reactions (IRs)
  • Pharmacokinetics (PK) of isatuximab
  • Minimal residual disease
  • Overall response rate
  • Overall survival
  • Event free survival
  • Duration of response
  • Relationship between clinical effects and CD38 receptor density and occupancy
Read the detailed description

The study included:

  • a screening period of up to (up to 3 weeks prior to the first study treatment administration);
  • a study treatment period [Day 1 to Day 57 for Acute Lymphoblastic Leukemia (ALL); Day 1 to Day 22 for Acute Myeloid Leukemia (AML)];
  • the period of aplasia followed by a recovery period;
  • an end of treatment (EOT) visit [within 30 days after hematological recovery;
  • a follow-up period (until final analysis cut off date).
03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia

Keywords

  • Anti-CD38 monoclonal antibody
04

Who can participate

Ages eligible
28 Days to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant 28 days to less than 18 years of age, at the time of signing the .
  • Participants must have had a confirmed diagnosis of Acute Lymphoblastic Leukemia (ALL) of T- or B-cell origin including T-lymphoblastic lymphoma (LBL), or relapsed Acute Myeloblastic Leukemia (AML) including participants with history of myelodysplasia.
  • Participants must have been previously treated for their disease and have relapsed or are refractory to most recent treatment. Participants in first or second relapse were eligible regardless of the remission duration.
  • Participants who had no more than 1 prior salvage therapy.
  • White Blood Cell (WBC) counts below 20 x10\^9/L on Day 1 before isatuximab administration

Exclusion criteria

Exclusion criteria:

  • Any serious active disease or co-morbid condition which, in the opinion of the Investigator, may interfere with the safety of the study treatment or the compliance with the study protocol.
  • Participants must have been off prior treatment with immunotherapy/ agents and chemotherapy for >2 weeks and must have recovered from acute toxicity before the first study treatment administration. Exceptions were participants who needed to receive cytoreductive chemotherapy in order to decrease tumor burden (the study treatment may have started earlier if necessitated by the patient's medical condition (eg, rapidly progressive disease) following discussion with the Sponsor).
  • Prior stem cell transplant within 3 months and/or evidence of active systemic (GVHD) and/or therapy for GVHD within 1 week before the first study treatment administration.
  • Participants with LBL with bone marrow blasts \<5%.
  • Participants with Burkitt-type ALL.
  • Acute leukemia with testicular or central nerve system involvement alone.
  • Participants who had developed therapy related acute leukemia.
  • (s) within 30 days prior to the first IMP administration or plans to receive such vaccines during the study until 90 days after the last IMP administration.
  • Participants with white blood cell count > 50 x10\^9/L at the time of screening visit.
  • Participants who had been exposed to anti-CD38 therapies within 6 months prior to Day-1.

The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia

    This arm includes participants from 3 cohorts: AML, T-ALL and B-ALL.; AML: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle; ALL: (Includes T-ALL and B-ALL) Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy.

    Drug: Isatuximab · Drug: Dexamethasone or equivalent · Drug: Fludarabine · Drug: Cytarabine · Drug: Liposomal daunorubicin · Drug: Daunorubicin (nonliposomal) · Drug: Idarubicin · Drug: Filgrastim or equivalent · Drug: Mitoxantrone · Drug: Doxorubicin · Drug: Vincristine · Drug: Pegaspargase (PEG) Asparaginase · Drug: Cyclophosphamide · Drug: Etoposide · Drug: Methotrexate · Drug: L - Asparginase · Drug: Hydroxyurea · Drug: L - Asparaginase (Erwinase)

Interventions

  • Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: Intravenous

    Also known as: SAR650984, Sarclisa

  • DrugDexamethasone or equivalent

    Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous

  • DrugFilgrastim or equivalent

    Pharmaceutical form: Solution for injection Route of administration: Intravenous

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

  • Pharmaceutical form: Solution for injection Route of administration: Intravenous infusion

  • DrugL - Asparginase

    Pharmaceutical form: Solution for injection Route of administration: Intramuscular

  • Pharmaceutical form: Solution for injection Route of administration: PO

  • Pharmaceutical form: Solution for injection Route of administration: Intramuscular

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Response (CR) Rate

    The complete response rate (CR + CRi \[complete response with incomplete peripheral recovery\]) was defined as the percentage of participants achieving complete response (CR + CRi) assessed by the investigator per National Comprehensive Cancer Network (NCCN) guidelines version 1.2018 criteria. CR was defined as \<5% blasts in a bone marrow aspirate (BMA) with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL); Absolute neutrophil count (ANC) \>=1000/microliter (mcL); platelets \>100000/mcL; red blood cell transfusion independence. If the physician documented transfusion dependency related to study treatment and not to the participant's underlying disease, CRi was reported. CRi met the same criteria as for CR, except neutrophils and/or platelets recovery (ANC \<1000/mcL or platelets \<100000/mcL).

    Time frame: From enrollment until the primary analysis completion date of 12 Sep 2022; the median duration of exposure was approximately 7 weeks

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as an AE which occurred after the first dose of study treatment administration until the last dose plus 30 days, or until the start of hematological recovery period or a new anti-leukemia/lymphoma therapy, whichever occurred first.

    Time frame: From the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort)

  2. Number of Participants With Infusion Reactions (IRs)

    An IR was an AE related to isatuximab typically with onset within 24 hours from the start of the isatuximab infusion and was reported by the investigator.

    Time frame: From the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort)

  3. B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab

    Plasma samples were collected at specified timepoints to determine the AUC of isatuximab.

    Time frame: From Week 0 to Week 1, Week 0 to Week 5, and Week 0 to Week 10

  4. AML: AUC of Isatuximab

    Plasma samples were collected at specified timepoints to determine the AUC of isatuximab.

    Time frame: From Week 0 to Week 1, Week 0 to Week 3, and Week 0 to Week 8

  5. B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)

    Plasma samples were collected at specified timepoints to determine the Ctrough of isatuximab.

    Time frame: Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 1 Day 29, Cycle 2 Day 43, Cycle 2 Day 57

  6. AML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)

    Plasma samples were collected at specified timepoints to determine the Ctrough of isatuximab.

    Time frame: Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 2 Day 15

  7. B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab

    Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.

    Time frame: At end of infusion on Cycle 1 Days 1 and 29

  8. AML: Ceoi of Isatuximab

    Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.

    Time frame: At end of infusion on Cycle 1 Days 1 and 15

  9. Number of Participants With Negative Minimal Residual Disease (MRD)

    MRD assessment was performed centrally by next generation sequencing using clonoSEQ and T-cell receptor assays for B-ALL and T-ALL cohorts respectively. It was performed by flow cytometry for AML cohort. Number of participants with CR or CRi who achieved negative MRD in bone marrow and blood was analyzed. In AML indication, peripheral blood tissue is not representative of the tumor burden and cannot be used to assess MRD.

    Time frame: From screening until the study completion date, approximately 45 months

  10. Overall Response Rate (ORR)

    ORR:Percentage of participants with CR/CRi or partial response (PR) for blood and bone marrow disease based on NCCN guideline. CR: \<5% blasts in BMA with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL);ANC \>=1000/mcL; platelets \>100000/mcL; RBC transfusion independence. If the physician documented transfusion dependency related to study treatment;not to participant's underlying disease, CRi was reported. CRi met the same criteria as CR, except neutrophils and/or platelets recovery (ANC \<1000/mcL or platelets \<100000/mcL). PR: \>50% decrease in the sum of the product of the greatest perpendicular diameters of the mediastinal enlargement. For participants with a previous positive positron emission tomography (PET) scan, a post-treatment PET was to be positive in at least 1 previously involved site.

    Time frame: From enrollment until the primary analysis completion date of 12 Sep 2022; the median duration of exposure was approximately 7 weeks

  11. Overall Survival (OS)

    Overall survival was defined as the time interval from the date of first study treatment administration to death from any cause. It was estimated using the Kaplan-Meier method. Confidence interval (CI) for Kaplan-Meier estimates were calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.

    Time frame: From first study treatment administration up to death due to any cause, a maximum of 45 months

  12. Event-Free Survival (EFS)

    EFS was defined as the time interval from the date of first study treatment administration to the date of the first of: completion or going off protocol induction/consolidation therapy without CR, relapse from CR, or death due to any cause, whichever occurred first. It was estimated using the Kaplan-Meier method. CI for Kaplan-Meier estimates are calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.

    Time frame: From study treatment administration up to the date of first documented disease progression or death due to any cause, a maximum of 45 months

  13. Duration of Response (DoR)

    Duration of response was defined as the time from the date of the first response to the date of first disease progression or death from any cause, whichever happens first. It was estimated using the Kaplan-Meier method. CI for Kaplan-Meier estimates are calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.

    Time frame: From first documented response up to the date of first documented disease progression or death due to any cause, a maximum of 45 months

  14. Cluster of Differentiation (CD)38 Receptor Density

    Blood samples were collected to assess CD38 receptor density as a predictive biomarker. It was assessed across complete responders and non-complete responders. The Antibody Binding Capacity (ABC) was calculated using the following equation: ABC = 10\^(Logarithm(Mean Fluorescence Intensity)\*a+b) where "a" was the slope and "b" was the Y-intercept of the calibration curve equation. Specific and absolute quantitative values (specific antibody-binding capacity \[sABC\]) of binding of the selected antibodies were calculated after subtraction of the negative isotypic immunoglobulin G (IgG) control.

    Time frame: Pre-dose on Day 1

  15. CD38 Receptor Occupancy

    Blood samples were collected to assess CD38 receptor occupancy as a pharmacodynamics marker. It was assessed across complete responders and non-complete responders. Multicolor flow cytometry assay was validated for CD38 receptor occupancy (CD38RO) quantification, based on the use of two murine monoclonal antibodies (MAbs), one competing with SAR650984 to determine the number of free CD38 receptors (MAb1) and one recognizing a different binding epitope on CD38 to measure the total number of receptors (MAb2) at the cell surface of the cancer cells. Cells were tagged with either MAb1 (Tube #1) or MAb2 (Tube #2). The percentage RO was calculated using the following equation: % CD38RO = \[(sABC MAb2 - sABC MAb1)/sABC MAb2\] X 100.

    Time frame: Pre-dose on Day 15

07

Results

Posted Nov 15, 2023
Limitations and caveats
The study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met) and not due to safety concerns.

Participant flow

This Phase II, open-label, single-arm study was conducted in 3 separate cohorts at 41 investigational sites in 16 countries. A total of 67 participants were enrolled between 06 Aug 2019 and 08 Jun 2022.

Participant flow — Overall Study
MilestoneB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Started271327
Completed19720
Not completed867
Withdrew: Adverse event, not related to coronavirus disease-2019 (covid-19)323
Withdrew: Progressive disease534
Withdrew: Other, not related to covid-19010

Outcome measures

PrimaryPercentage of Participants With Complete Response (CR) Rate

The complete response rate (CR + CRi \[complete response with incomplete peripheral recovery\]) was defined as the percentage of participants achieving complete response (CR + CRi) assessed by the investigator per National Comprehensive Cancer Network (NCCN) guidelines version 1.2018 criteria. CR was defined as \<5% blasts in a bone marrow aspirate (BMA) with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL); Absolute neutrophil count (ANC) \>=1000/microliter (mcL); platelets \>100000/mcL; red blood cell transfusion independence. If the physician documented transfusion dependency related to study treatment and not to the participant's underlying disease, CRi was reported. CRi met the same criteria as for CR, except neutrophils and/or platelets recovery (ANC \<1000/mcL or platelets \<100000/mcL).

Time frame:
From enrollment until the primary analysis completion date of 12 Sep 2022; the median duration of exposure was approximately 7 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) Rate
percentage of participantsB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Percentage of Participants With Complete Response (CR) Rate52.045.560.9
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as an AE which occurred after the first dose of study treatment administration until the last dose plus 30 days, or until the start of hematological recovery period or a new anti-leukemia/lymphoma therapy, whichever occurred first.

Time frame:
From the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Any TEAE271326
Any TESAE191217
SecondaryNumber of Participants With Infusion Reactions (IRs)

An IR was an AE related to isatuximab typically with onset within 24 hours from the start of the isatuximab infusion and was reported by the investigator.

Time frame:
From the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort)
Reported as:
Count of participants · Participants
Number of Participants With Infusion Reactions (IRs)
ParticipantsB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Number of Participants With Infusion Reactions (IRs)9515
SecondaryB-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab

Plasma samples were collected at specified timepoints to determine the AUC of isatuximab.

Time frame:
From Week 0 to Week 1, Week 0 to Week 5, and Week 0 to Week 10
Reported as:
Mean · mg*hour (h)/Liter (L)
B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab
mg*hour (h)/Liter (L)B-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)
Week 0 to Week 131703 ± 1004829057 ± 8294
Week 0 to Week 5299071 ± 127581289167 ± 93095
Week 0 to Week 10582686 ± 316749540375 ± 233411
SecondaryAML: AUC of Isatuximab

Plasma samples were collected at specified timepoints to determine the AUC of isatuximab.

Time frame:
From Week 0 to Week 1, Week 0 to Week 3, and Week 0 to Week 8
Reported as:
Mean · mg*h/L
AML: AUC of Isatuximab
mg*h/LAcute Myeloid Leukemia (AML)
Week 0 to Week 128592 ± 6858
Week 0 to Week 3130862 ± 40827
Week 0 to Week 8291962 ± 112222
SecondaryB-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)

Plasma samples were collected at specified timepoints to determine the Ctrough of isatuximab.

Time frame:
Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 22, Cycle 1 Day 29, Cycle 2 Day 43, Cycle 2 Day 57
Reported as:
Mean · microgram/milliliter (mcg/mL)
B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
microgram/milliliter (mcg/mL)B-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)
Cycle 1: Day 8114 ± 45.7127 ± 49.9
Cycle 1: Day 15272 ± 118263 ± 103
Cycle 1: Day 22388 ± 163323 ± 206
Cycle 1: Day 29475 ± 174426 ± 209
Cycle 2: Day 43504 ± 296357 ± NA
Cycle 2: Day 57531 ± 224478 ± 261
SecondaryAML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)

Plasma samples were collected at specified timepoints to determine the Ctrough of isatuximab.

Time frame:
Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 2 Day 15
Reported as:
Mean · mcg/mL
AML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
mcg/mLAcute Myeloid Leukemia (AML)
Cycle 1: Day 8126 ± 41.0
Cycle 1: Day 15217 ± 60.6
Cycle 2: Day 1115 ± 94.2
Cycle 2: Day 15420 ± 205
SecondaryB-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab

Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.

Time frame:
At end of infusion on Cycle 1 Days 1 and 29
Reported as:
Mean · mcg/mL
B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab
mcg/mLB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)
Cycle 1: Day 1452 ± 344259 ± 120
Cycle 1: Day 29835 ± 366745 ± 330
SecondaryAML: Ceoi of Isatuximab

Ceoi is the plasma concentration observed at the end of intravenous infusion of isatuximab.

Time frame:
At end of infusion on Cycle 1 Days 1 and 15
Reported as:
Mean · mcg/mL
AML: Ceoi of Isatuximab
mcg/mLAcute Myeloid Leukemia (AML)
Cycle 1: Day 1363 ± 110
Cycle 1: Day 15562 ± 176
SecondaryNumber of Participants With Negative Minimal Residual Disease (MRD)

MRD assessment was performed centrally by next generation sequencing using clonoSEQ and T-cell receptor assays for B-ALL and T-ALL cohorts respectively. It was performed by flow cytometry for AML cohort. Number of participants with CR or CRi who achieved negative MRD in bone marrow and blood was analyzed. In AML indication, peripheral blood tissue is not representative of the tumor burden and cannot be used to assess MRD.

Time frame:
From screening until the study completion date, approximately 45 months
Reported as:
Count of participants · Participants
Number of Participants With Negative Minimal Residual Disease (MRD)
ParticipantsB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Blood, 10^-631—
Bone marrow, 10^-6020
Bone marrow, 10^-3——0
SecondaryOverall Response Rate (ORR)

ORR:Percentage of participants with CR/CRi or partial response (PR) for blood and bone marrow disease based on NCCN guideline. CR: \<5% blasts in BMA with spicules; no circulating blasts (ALL)/no blasts with Auer rods (AML) or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement (ALL), trilineage hematopoiesis (ALL);ANC \>=1000/mcL; platelets \>100000/mcL; RBC transfusion independence. If the physician documented transfusion dependency related to study treatment;not to participant's underlying disease, CRi was reported. CRi met the same criteria as CR, except neutrophils and/or platelets recovery (ANC \<1000/mcL or platelets \<100000/mcL). PR: \>50% decrease in the sum of the product of the greatest perpendicular diameters of the mediastinal enlargement. For participants with a previous positive positron emission tomography (PET) scan, a post-treatment PET was to be positive in at least 1 previously involved site.

Time frame:
From enrollment until the primary analysis completion date of 12 Sep 2022; the median duration of exposure was approximately 7 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Overall Response Rate (ORR)52.0 (37.5 to 66.2)54.5 (31.8 to 75.9)65.2 (49.7 to 78.6)
SecondaryOverall Survival (OS)

Overall survival was defined as the time interval from the date of first study treatment administration to death from any cause. It was estimated using the Kaplan-Meier method. Confidence interval (CI) for Kaplan-Meier estimates were calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.

Time frame:
From first study treatment administration up to death due to any cause, a maximum of 45 months
Reported as:
Median · months
Overall Survival (OS)
monthsB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Overall Survival (OS)12.09 (3.975 to NA)6.85 (2.201 to NA)9.40 (5.947 to NA)
SecondaryEvent-Free Survival (EFS)

EFS was defined as the time interval from the date of first study treatment administration to the date of the first of: completion or going off protocol induction/consolidation therapy without CR, relapse from CR, or death due to any cause, whichever occurred first. It was estimated using the Kaplan-Meier method. CI for Kaplan-Meier estimates are calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.

Time frame:
From study treatment administration up to the date of first documented disease progression or death due to any cause, a maximum of 45 months
Reported as:
Median · months
Event-Free Survival (EFS)
monthsB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Event-Free Survival (EFS)2.23 (1.413 to NA)2.14 (1.347 to NA)5.65 (1.347 to NA)
SecondaryDuration of Response (DoR)

Duration of response was defined as the time from the date of the first response to the date of first disease progression or death from any cause, whichever happens first. It was estimated using the Kaplan-Meier method. CI for Kaplan-Meier estimates are calculated with log-log transformation of survival function and methods of Brookmeyer and Crowley.

Time frame:
From first documented response up to the date of first documented disease progression or death due to any cause, a maximum of 45 months
Reported as:
Median · months
Duration of Response (DoR)
monthsB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Duration of Response (DoR)7.26 (NA to NA)1.18 (0.887 to NA)4.40 (NA to NA)
SecondaryCluster of Differentiation (CD)38 Receptor Density

Blood samples were collected to assess CD38 receptor density as a predictive biomarker. It was assessed across complete responders and non-complete responders. The Antibody Binding Capacity (ABC) was calculated using the following equation: ABC = 10\^(Logarithm(Mean Fluorescence Intensity)\*a+b) where "a" was the slope and "b" was the Y-intercept of the calibration curve equation. Specific and absolute quantitative values (specific antibody-binding capacity \[sABC\]) of binding of the selected antibodies were calculated after subtraction of the negative isotypic immunoglobulin G (IgG) control.

Time frame:
Pre-dose on Day 1
Reported as:
Mean · sABC
Cluster of Differentiation (CD)38 Receptor Density
sABCB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Blood blast cells: CR/CRi20345.6 ± 23439.712780.0 ± 15559.219502.0 ± 20919.7
Blood blast cells: Non CR/CRi;31080.0 ± 2397.122952.0 ± NA9815.0 ± 4203.0
Blood immune cells (Natural Killer [NK] cells): CR/CRi13506.2 ± 3018.622639.0 ± 1796.111220.3 ± 3764.6
Blood immune cells (NK cells): Non CR/CRi16650.0 ± 851.433859.0 ± NA22530.0 ± 685.9
SecondaryCD38 Receptor Occupancy

Blood samples were collected to assess CD38 receptor occupancy as a pharmacodynamics marker. It was assessed across complete responders and non-complete responders. Multicolor flow cytometry assay was validated for CD38 receptor occupancy (CD38RO) quantification, based on the use of two murine monoclonal antibodies (MAbs), one competing with SAR650984 to determine the number of free CD38 receptors (MAb1) and one recognizing a different binding epitope on CD38 to measure the total number of receptors (MAb2) at the cell surface of the cancer cells. Cells were tagged with either MAb1 (Tube #1) or MAb2 (Tube #2). The percentage RO was calculated using the following equation: % CD38RO = \[(sABC MAb2 - sABC MAb1)/sABC MAb2\] X 100.

Time frame:
Pre-dose on Day 15
Reported as:
Mean · percent receptor occupancy
CD38 Receptor Occupancy
percent receptor occupancyB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)
Blood plasma cells: CR/CRi—40.5 ± 30.4—
Blood plasma cells: Non CR/CRi;44.0 ± NA55.0 ± NA—
Blood NK cells: CR/CRi55.6 ± 6.966.7 ± 2.1—
Blood NK cells: Non CR/CRi61.3 ± 3.570.0 ± NA—

Adverse events

Collected over TEAEs were collected from the time of the first treatment administration (Day 1) up to 30 days after the last treatment (maximum duration of exposure of 13.1 weeks for B-ALL cohort, 10.7 weeks for T-ALL cohort and 7.1 weeks for AML cohort). All-cause mortality (Deaths) was collected for the entire study duration, a maximum of 45 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B-cell Acute Lymphoblastic Leukemia (B-ALL)17/27 (63%)19/27 (70.4%)26/27 (96.3%)
T-cell Acute Lymphoblastic Leukemia (T-ALL)8/13 (61.5%)12/13 (92.3%)12/13 (92.3%)
Acute Myeloid Leukemia (AML)18/27 (66.7%)17/27 (63%)24/27 (88.9%)
All Participants43/67 (64.2%)48/67 (71.6%)62/67 (92.5%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)All Participants
Febrile NeutropeniaBlood and lymphatic system disorders10/275/137/2722/67
SepsisInfections and infestations1/272/131/274/67
Septic ShockInfections and infestations3/272/133/278/67
Device Related InfectionInfections and infestations0/271/130/271/67
Disseminated AspergillosisInfections and infestations0/271/130/271/67
Escherichia SepsisInfections and infestations0/271/130/271/67
Fungal InfectionInfections and infestations1/271/130/272/67
Neutropenic SepsisInfections and infestations0/271/130/271/67
PeritonitisInfections and infestations0/271/130/271/67
Rhinovirus InfectionInfections and infestations0/271/130/271/67
Most frequent other events
Showing 10 of 77
Most frequent other events
EventB-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)All Participants
Infusion Related ReactionInjury, poisoning and procedural complications8/274/1314/2726/67
PyrexiaGeneral disorders10/274/1312/2726/67
HypertensionVascular disorders0/275/133/278/67
StomatitisGastrointestinal disorders10/274/138/2722/67
VomitingGastrointestinal disorders6/273/1310/2719/67
HeadacheNervous system disorders3/273/139/2715/67
NauseaGastrointestinal disorders9/273/136/2718/67
Decreased AppetiteMetabolism and nutrition disorders1/272/138/2711/67
DiarrhoeaGastrointestinal disorders4/273/138/2715/67
ConstipationGastrointestinal disorders3/272/137/2712/67

Baseline characteristics

The All-treated (AT) population consisted of all participants who received at least 1 dose (even incomplete) of study treatment.

Age, Continuous
Age, Continuous(years)B-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)Total
Mean8.22 ± 3.928.72 ± 4.159.04 ± 5.418.65 ± 4.56
Sex: Female, Male
Sex: Female, Male(Participants)B-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)Total
Female1041226
Male1791541
Race (NIH/OMB)
Race (NIH/OMB)(Participants)B-cell Acute Lymphoblastic Leukemia (B-ALL)T-cell Acute Lymphoblastic Leukemia (T-ALL)Acute Myeloid Leukemia (AML)Total
American Indian or Alaska Native3003
Asian1146
Native Hawaiian or Other Pacific Islander0000
Black or African American1124
White1771539
More than one race1001
Unknown or Not Reported44614
08

Study locations

41 sites
  • Sarah Cannon Research Institute-Site Number:8400001
    Nashville, Tennessee 37203, United States
  • Children's Medical Center of Dallas-Site Number:8400002
    Dallas, Texas 75235, United States
  • Investigational Site Number :0320002
    CABA, Buenos Aires C1181ACH, Argentina
  • Investigational Site Number :0320006
    Capital Federal, Buenos Aires C1425DUC, Argentina
  • Investigational Site Number :0320005
    Buenos Aires, C1118AAT, Argentina
  • Investigational Site Number :0320004
    Buenos Aires, C1245AAM, Argentina
  • Investigational Site Number :0760013
    Curitiba, Paraná 80250-060, Brazil
  • Investigational Site Number :0760006
    Curitiba, Paraná 81520-060, Brazil
  • Investigational Site Number :0760007
    Porto Alegre, Rio Grande do Sul 90035 003, Brazil
  • Investigational Site Number :0760010
    Jaú, São Paulo 17210-070, Brazil
  • Investigational Site Number :0760009
    Ribeirão Preto, São Paulo 14048-900, Brazil
  • Investigational Site Number :0760001
    São Paulo, São Paulo 08270-070, Brazil
  • Investigational Site Number :0760004
    São Paulo, São Paulo 4023-062, Brazil
  • Investigational Site Number :2080001
    Copenhagen, 2100, Denmark
  • Investigational Site Number :2500002
    Lille, 59037, France
  • Investigational Site Number :2500003
    Lyon, 69008, France
  • Investigational Site Number :2500001
    Paris, 75571, France
  • Investigational Site Number :2500004
    Paris, 75935, France
  • Investigational Site Number :2760005
    Erlangen, 91054, Germany
  • Investigational Site Number :2760003
    Hamburg, 20246, Germany
  • Investigational Site Number :2760006
    Münster, 48149, Germany
  • Investigational Site Number :3000001
    Athens, 115 27, Greece
  • Investigational Site Number :3480002
    Budapest, 1094, Hungary
  • Investigational Site Number :3800002
    Genoa, Liguria 16147, Italy
  • Investigational Site Number :3800001
    Monza, Lombardy 20900, Italy
  • Investigational Site Number :3800003
    Turin, Piedmont 10126, Italy
  • Investigational Site Number :3800005
    Verona, Veneto 37126, Italy
  • Investigational Site Number :4840001
    Monterrey, Nuevo León 64460, Mexico
  • Investigational Site Number :4840005
    Col. Rancho Menchaca, Querétaro 76140, Mexico
  • Investigational Site Number :5280001
    Utrecht, 3584 CS, Netherlands
  • Investigational Site Number :5780001
    Bergen, 5021, Norway
  • Investigational Site Number :5780002
    Oslo, 0342, Norway
  • Investigational Site Number :6040001
    Arequipa, Peru
  • Investigational Site Number :6040002
    Lima, 34, Peru
  • Investigational Site Number :6200002
    Coimbra, 3000-602, Portugal
  • Investigational Site Number :6200001
    Lisbon, 1099-023, Portugal
  • Investigational Site Number :6200003
    Porto, 4200-162, Portugal
  • Investigational Site Number :4100001
    Seoul, Seoul-teukbyeolsi 03080, South Korea
  • Investigational Site Number :4100002
    Seoul, Seoul-teukbyeolsi 06351, South Korea
  • Investigational Site Number :4100004
    Seoul, Seoul-teukbyeolsi 137-701, South Korea
  • Investigational Site Number :7520001
    Gothenburg, 416 85, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Sep 2022, 37 months.

Results were first posted in Nov 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2019
First posted
Mar 4, 2019
StartActual
Aug 6, 2019
Primary completionActual
Sep 12, 2022
CompletionActual
May 26, 2023
Results first posted
Nov 15, 2023
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03860844
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 4, 2019
Start date
Aug 6, 2019
Primary completion
Sep 12, 2022
Completion
May 26, 2023
Results posted
Nov 15, 2023
Last update
Sep 9, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion